| NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) | RECRUITING | PHASE2, PHASE3 | 2023-01-04 | 2028-08 | 2026-02 |
| NCT04571970 | RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) | COMPLETED | PHASE1, PHASE2 | 2021-03-11 | 2024-05-23 | 2023-05-09 |
| NCT03580083 | RGX-111 Gene Therapy in Patients With MPS I | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-04-03 | 2024-10 | 2023-03-01 |
| NCT03566043 | CAMPSIITEā¢ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2018-09-27 | 2025-08 | 2023-11-27 |
| NCT03066258 | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | COMPLETED | PHASE1, PHASE2 | 2017-03-29 | 2021-06-17 | 2019-11-24 |
| NCT02651675 | A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) | TERMINATED | PHASE1, PHASE2 | 2016-03 | 2020-11-27 | 2020-11-27 |